
We enjoyed seeing you at the 40
th anniversary of the San Antonio Breast Cancer Symposium (SABCS) last week and hope you had the opportunity to connect with your colleagues and meet your objectives at this informative conference.
Myriad is proud to have been an exhibitor at this year’s SABCS and are excited to share some of our conference highlights with you.
Scientific Sessions
myRisk® Hereditary Cancer with riskScore™ Spotlight Presentation
Title: Development and Validation of a Combined Residual Risk Score to Predict Breast Cancer Risk in Unaffected Women Negative for Mutations on a Multi-Gene Hereditary Cancer Panel.
Presenter: Elisha Hughes, PhD, Myriad Genetic Laboratories
The highly anticipated validation study for riskScore™, recently added to Myriad’s myRisk® Hereditary Cancer panel, was featured in a spotlight session that attracted much excitement during the panel discussion following the release of the data.
- riskScore is a clinically validated breast cancer risk model that predicts the patient’s risk of breast cancer using 80+ SNPs and the Tyrer-Cuzick model to provide a combined lifetime and 5-year risk score that accounts for clinical, familial and genetic variables.
- The results of the validation data shows that riskScore was statistically significantly superior to Tyrer-Cuzick alone for both 5-year and lifetime risk of breast cancer.
- riskScore represents a more comprehensive assessment of breast cancer risk for unaffected women of European descent who tested negative for hereditary breast cancer mutations.
- Myriad is currently planning to publish this study in a peer-reviewed journal.
EndoPredict is a second-generation prognostic gene expression test for patients with breast cancer. Myriad presented results of two important studies at SABCS related to EndoPredict that demonstrates the importance of this test in predicting disease recurrence and response to therapy.
EndoPredict Podium Presentation
Title: The EndoPredict (EP) score predicts residual cancer burden to neoadjuvant chemotherapy (NCT) and to neuroendocrine therapy (NET) in HR+/HER2- breast cancer patients from ABCSG34 (Austrian Breast and Colorectal Cancer Study Group Trial-34).
Presenter: Peter Dubsky, M.D., Medical University of Vienna, Austria and the Breast Center St. Anna Klinik, Lucerne.
- This study was designed to show the predictive value of the EP 12-gene molecular score for tumor response to NCT and NET.
- The results indicate that women with a high EP score responded better to NCT than those with a low score, while those with a low EP score responded better to NET.
- The results show that 26.4 percent of those with a high score showed a good tumor response (RCB0/I) to neoadjuvant chemotherapy, while all patients with a low score showed only a poor tumor response (Table 1). In the “luminal A” group receiving neoendocrine therapy, 39 patients had a high EP score and 44 had a low EP score. The results show that 27.3 percent of those with a low EndoPredict score and 7.7 percent with a high score achieved excellent tumor response (RCB0/I) to neoendocrine therapy (Table 1).
EndoPredict Poster Presentation
Title: Prognostic performance of EndoPredict in invasive lobular carcinoma
Presenter: Ivana Sestak, Ms, PhD, Queen Mary, University of London | QMUL · Wolfson Institute of Preventive Medicine
- This study evaluated the role of EP molecular-clinical score (EPclin) for the prediction of distant recurrence in women diagnosed with invasive lobular carcinoma (ILC) compared to those with invasive ductal carcinoma (IDC).
- This results show that EP provided significant power for predicting distant recurrence in patients with both ILC and IDC.
EMBRACA General Session
Title: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced germline BRCA-mutation breast cancer.
Presenter: Jennifer K. Litton, M.D., MD Anderson Cancer Center
- In the EMBRACA trial of patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer, talazoparib showed a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy (HR=0.54, P<0.0001, 8.6 months in the talazoparib arm vs. 5.6 months in the chemotherapy arm).
- Myriad’s BRACAnalysis CDx® test was used to identify patients with germlineBRCA1/2 mutations who were eligible for the EMBRACA trial.
- This study demonstrated the efficacy of another PARP inhibitor, talazoparib, for patients with locally advanced or metastatic breast cancer.
- Pending FDA review, these data may represent another treatment option for patients with advanced breast cancer and further emphasize the importance of knowing BRCA status in all patients with HER2-negative metastatic breast cancer.
For details on Myriad’s scientific presentations at SABCS, please visit: http://myriadpro.com/publications/